stockrow
Saturday 7 November 2026
Export HCWB’s income statement to Excel — free account
HCW Biologics Inc.
HCWB Healthcare Biotechnology
HCW Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54,200.00, down 97.9% from fiscal 2024.
- Revenue
- +1,954.6%
- EPS
- +71.6%
- Free cash flow
- −20.8%
- Total debt
- −3.34%
Quarter to June 2026, against a year earlier
1.02
0.02
−1.92%
Follow HCWB
Alert me
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 3 | 3 |
P/E ratio |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | 2.90 | (4.68) | (8.45) | (8.83) |
P/S ratio |
— | — | 0.00 | — | 10.45 | 15.17 | 6.74 | 37.48 |
Altman Z″-Score (non-manufacturers) |
— | — | (1.88) | — | 3.21 | (13.72) | (22.77) | (22.93) |
P/FCF ratio |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | 3.67 | (6.27) | (9.28) |
P/Operating CF |
— | — | (31.30) | — | (18.53) | (11.07) | (6.11) | (0.61) |
P/B ratio |
— | — | 0.00 | — | 1.88 | 3.20 | 0.00 | 0.74 |
Price to Tangible BV |
— | — | 0.00 | — | 1.88 | 3.20 | 0.00 | 0.74 |
EV/Sales |
— | — | 0.00 | — | 6.63 | 16.18 | 10.26 | 133.69 |
EV/EBITDA |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | (2.96) | — | (4.29) | (2.04) | (1.85) | (0.54) |
EV/FCF |
— | — | (2.90) | — | (2.16) | (1.60) | (1.82) | (0.53) |
Quick Ratio |
— | 6.90 | 10.94 | 15.87 | 10.99 | 0.59 | 0.18 | 0.09 |
Current Ratio |
— | 7.53 | 12.14 | 17.44 | 11.52 | 0.73 | 0.19 | 0.11 |
Net Debt/EBITDA |
— | 1.06 | 1.50 | 2.86 | 1.79 | (0.11) | (0.32) | (0.40) |
Debt/Assets |
0.00% | 0.00% | 3.68% | 0.00% | 13.69% | 22.11% | 45.28% | 27.77% |
Debt/Equity |
— | 0.00 | (0.03) | 0.00 | 0.17 | 0.47 | (2.02) | 2.46 |
Asset Turnover |
— | 0.00 | 0.32 | 0.00 | 0.13 | 0.08 | 0.09 | 0.00 |
Operating CF/Net income |
— | 0.87 | 1.47 | 0.85 | 0.70 | 0.90 | 0.47 | 0.60 |
Capex/Depreciation |
— | 0.00 | (0.33) | (0.09) | (14.31) | (5.46) | (0.22) | 0.00 |
Interest Coverage |
— | (203.46) | (261.19) | — | (119.01) | (90.87) | (45.02) | (15.58) |
| — | 58.97% | 53.60% | (74.62%) | (33.63%) | (98.23%) | (897.37%) | 1,113.43% | |
| — | (154.63%) | (55.56%) | (37.33%) | (29.71%) | (66.37%) | (102.21%) | (81.45%) | |
ROIC |
— | 0.00% | 0.00% | (57.70%) | (80.03%) | (99.40%) | (819.04%) | (107.94%) |
Return on Tangible Assets |
— | (86.80%) | (55.43%) | (32.75%) | (35.55%) | (138.02%) | 2,942.07% | (1,060.53%) |
Average Days of Receivables |
— | — | 222.57 | 0.00 | 22.68 | 197.26 | 82.79 | 216.85 |
Research and Development Expense of Revenue |
— | 0.00% | 176.96% | 0.00% | 138.92% | 270.12% | 248.91% | 10,042.25% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 65.10% | 0.00% | 123.87% | 238.56% | 265.56% | 14,209.04% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.53% | 0.00% | 16.66% | 35.32% | 39.31% | 1,418.08% |
Graham Net Nets |
— | — | (0.85) | — | 0.35 | (0.20) | (1.81) | (9.57) |
Graham Number |
— | — | 3,057.84 | — | 0.00 | 0.00 | 364.64 | 0.00 |
Earnings Yield |
— | — | (38.19%) | — | (21.39%) | (58.32%) | (131.83%) | (1,216.15%) |
Free Cash Flow Yield |
— | — | (28.82%) | — | (29.42%) | (66.61%) | (83.70%) | (670.84%) |
Revenue per Share |
— | 0.00 | 208.11 | 0.00 | 45.02 | 18.98 | 15.87 | 0.16 |
Operating CF per Share |
— | (0.18) | (529.51) | (140.35) | (69.57) | (150.39) | (87.99) | (38.29) |
Capex per Share |
— | 0.00 | (9.48) | (0.60) | (68.82) | (41.43) | (1.62) | 0.00 |
Free Cash Flow per Share |
— | (0.18) | (538.98) | (140.96) | (138.39) | (191.83) | (89.60) | (38.29) |
Cash per Share |
— | 0.20 | 429.23 | 469.49 | 214.75 | 24.02 | 28.91 | 5.58 |
Shareholders Equity per Share |
— | 0.25 | (848.65) | 654.64 | 250.69 | 89.92 | (41.87) | 7.91 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.25 | (848.65) | 654.64 | 250.69 | 89.92 | (41.87) | 7.91 |
Free Cash Flow |
— | (6.77) | (10.62) | (11.02) | (20.66) | (28.72) | (14.49) | (13.39) |
Working Capital |
— | 6.96 | 11.15 | 38.16 | 31.11 | (2.34) | (23.93) | (18.78) |
Capital Expenditures |
— | (1.46) | (0.19) | (0.05) | (10.28) | (6.20) | (0.26) | — |
Net Current Asset Value |
— | 6.96 | (19.97) | 38.16 | 24.69 | (8.65) | (31.31) | (19.47) |
EV/EBIT |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.05 | 0.00 | 1.53 | 2.18 | 0.10 | 0.00 |
Price to Operating Income |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.21 | 0.35 | 0.49 | 0.07 | 0.06 | 0.05 | 0.05 |
Cash ROIC |
— | (41.36%) | 137.98% | (12.54%) | (27.22%) | (122.93%) | (124.94%) | (116.18%) |
Accounts Receivable Turnover |
— | — | 3.11 | 0.00 | 24.41 | 2.91 | 2.42 | 0.18 |
Accounts Payable Turnover |
— | 1.54 | 0.00 | 2.87 | 5.70 | 0.62 | 0.11 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 339.47 | 0.00 | 150.20 | 108.22 | 986.69 | 5,071.10 | 110,537.81 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 1.32 | 1.32 | 0.28 | 0.98 | 1.06 | 0.31 |
Average Payables |
— | 0.27 | 0.27 | 0.19 | 0.72 | 3.70 | 14.25 | 17.74 |
Average Assets |
— | 5.03 | 12.73 | 34.46 | 50.16 | 37.66 | 29.38 | 27.38 |
Average Common Equity |
— | (13.20) | (13.20) | 17.24 | 44.31 | 25.45 | 3.35 | (2.00) |
Columns are period end dates · fundamentals updated 26 Oct 2026